Business Model Breakdown
How Aldeyra Therapeutics Inc Makes Money
ALDX
Market Cap
$104M
The Short Version
Aldeyra Therapeutics is a clinical-stage biotechnology company focused on developing novel treatments for inflammatory, autoimmune, and metabolic diseases. Its business model relies on identifying and developing drug candidates through clinical trials, with the ultimate goal of obtaining regulatory approval from agencies like the FDA. Once approved, the company would generate revenue through direct commercialization of its products or through licensing agreements with larger pharmaceutical partners. Currently, it operates as a research and development entity with no commercial products, primarily burning cash to fund its drug discovery and clinical development efforts.
Where the Revenue Comes From
No current revenue streams ($0 reported).
Who buys: Future customers would primarily be healthcare providers and indirectly, patients suffering from the targeted inflammatory and immune-mediated diseases.
Why It Works (Competitive Advantages)
- ✔Proprietary compound (reproxalap), but regulatory failure diminishes its value.
- ✔Pipeline of other early-stage candidates targeting inflammatory diseases.
Economic Moat: None (Intangible Assets/IP (severely challenged by regulatory setbacks))
What Our Analysis Says
DVR Score as of May 10, 2026
Aldeyra's score remains extremely low due to the persistent and catastrophic impact of the third Complete Response Letter (CRL) from the FDA for reproxalap in dry eye disease. This event, which 'effectively eliminated the primary multi-billion dollar market opportunity,' is not reversed by a recent PDUFA extension which still indicates regulatory hurdles. The ongoing securities class-action lawsuits continue to pose significant legal and financial threats. While Q1 2026 reported a narrower loss than estimates, the company remains pre-revenue with substantial cash burn, lacking a clear path to market leadership or profitability for its key asset within the 3-5 year timeframe. The risk/reward profile remains heavily skewed towards risk, with almost no immediate reward catalysts or evidence of 10x growth potential.